Suppr超能文献

中国某单一中心大量三阴性乳腺癌的组织病理学与临床病理分析:组织学亚型分类及分级必要性的证据

Histo- and clinico-pathological analysis of a large series of triple-negative breast cancer in a single center in China: Evidences on necessity of histological subtyping and grading.

作者信息

Zhang Shuang, Huang Sixia, Zhang Hong, Li Dong, Li Xin, Cheng Yuanjia, Liu Qian, Xu Ling, Wang Yue, Liu Yinhua, Li Ting

机构信息

Department of Pathology, Peking University First Hospital, Beijing 100034, China.

Breast Disease Center, Peking University First Hospital, Beijing 100034, China.

出版信息

Chin J Cancer Res. 2020 Oct 31;32(5):580-595. doi: 10.21147/j.issn.1000-9604.2020.05.03.

Abstract

OBJECTIVE

To investigate histo-pathological distribution and clinico-pathological significance in a large Chinese triple-negative breast cancer (TNBC) patients serials based on the latest understanding of its clinico-pathological diversity, and to provide more information to clinicians to improve precision of individualized treatment of TNBC.

METHODS

A retrospective analysis was performed on patients with TNBC at Breast Disease Center, Peking University First Hospital between January 2010 and December 2019. Histo- and clinico-pathological characteristics were analyzed by Chi-square test and Student's -test, and prognoses were calculated using Kaplan-Meier method and a Cox proportionate hazards model. Bonferroni correction was used to correct for multiple comparison.

RESULTS

Conventional type of TNBC (cTNBC) were identified in 73.7% of 582 TNBC, while special type of TNBC (sTNBC) were 26.3%, including 71 apocrine carcinoma, 20 medullary carcinoma, 31 metaplastic carcinoma, 18 invasive lobular carcinoma, 7 invasive micropapillary carcinoma, 5 adenoid cystic carcinoma and 1 acinic cell carcinoma. Compared to sTNBC, cTNBC was associated with high histologic grade (P<0.001) and lower androgen receptor (AR) expression (P<0.001). TNM stage of low-grade cTNBC was significantly lower than that of high-grade cTNBC (P=0.002). Although no significant difference, there was a trend that the rate of 5-year disease-free survival (DFS) and 5-year overall survival (OS) were longer in high-grade cTNBC than in high-grade sTNBC (P=0.091 and 0.518), and were longer in low-grade sTNBC than in high-grade sTNBC (P=0.051 and 0.350). Metaplastic carcinomas showed larger tumor size (P=0.008) and higher proliferative Ki67 index (P=0.004) than cTNBCs.

CONCLUSIONS

Results from our cohort imply that sub-categorization or subtyping and histological grading could be meaningful in pathological evaluation of TNBC, and need to be clarified in more large collections of TNBC.

摘要

目的

基于对三阴性乳腺癌(TNBC)临床病理多样性的最新认识,在中国大量TNBC患者系列中研究组织病理学分布及临床病理意义,为临床医生提供更多信息,以提高TNBC个体化治疗的精准性。

方法

对2010年1月至2019年12月北京大学第一医院乳腺疾病中心的TNBC患者进行回顾性分析。采用卡方检验和学生t检验分析组织病理学和临床病理特征,使用Kaplan-Meier法和Cox比例风险模型计算预后。采用Bonferroni校正进行多重比较校正。

结果

582例TNBC中,73.7%为传统型TNBC(cTNBC),26.3%为特殊型TNBC(sTNBC),包括71例大汗腺癌、20例髓样癌、31例化生性癌、18例浸润性小叶癌、7例浸润性微乳头状癌、5例腺样囊性癌和1例腺泡细胞癌。与sTNBC相比,cTNBC与高组织学分级相关(P<0.001),雄激素受体(AR)表达较低(P<0.001)。低级别cTNBC的TNM分期显著低于高级别cTNBC(P=0.002)。尽管无显著差异,但高级别cTNBC的5年无病生存率(DFS)和5年总生存率(OS)有长于高级别sTNBC的趋势(P=0.091和0.518),低级别sTNBC的DFS和OS长于高级别sTNBC(P=0.051和0.350)。化生性癌的肿瘤大小大于cTNBC(P=0.008),增殖性Ki67指数高于cTNBC(P=0.004)。

结论

我们队列的结果表明,在TNBC的病理评估中,亚分类或亚型划分以及组织学分级可能具有意义,需要在更多的TNBC大样本研究中进一步明确。

相似文献

3
Disease Behavior and Treatment Response of Special Histological Types of Triple-Negative Breast Cancer.
Clin Breast Cancer. 2022 Dec;22(8):e892-e900. doi: 10.1016/j.clbc.2022.08.006. Epub 2022 Aug 20.
4
Histologic heterogeneity of triple negative breast cancer: A National Cancer Centre Database analysis.
Eur J Cancer. 2018 Jul;98:48-58. doi: 10.1016/j.ejca.2018.04.011. Epub 2018 Jun 2.
5
Prognostic impact of histological subtyping in triple-negative breast cancer.
Hum Pathol. 2024 Oct;152:105640. doi: 10.1016/j.humpath.2024.105640. Epub 2024 Aug 10.
10
Androgen receptor expression predicts decreased survival in early stage triple-negative breast cancer.
Ann Surg Oncol. 2015 Jan;22(1):82-9. doi: 10.1245/s10434-014-3984-z. Epub 2014 Aug 22.

引用本文的文献

1
Medullary breast cancer and germline BRCA1 mutations: a possible criterion for genetic testing.
Hered Cancer Clin Pract. 2025 Sep 1;23(1):20. doi: 10.1186/s13053-025-00321-y.
2
Cyclin-dependent kinase 7 (CDK7) inhibitors as a novel therapeutic strategy for different molecular types of breast cancer.
Br J Cancer. 2024 May;130(8):1239-1248. doi: 10.1038/s41416-024-02589-8. Epub 2024 Feb 14.
4
[Clinicopathological features and prognosis of hormone receptor-positive/human epidermal growth factor receptor 2-negative breast cancer].
Beijing Da Xue Xue Bao Yi Xue Ban. 2022 Oct 18;54(5):853-862. doi: 10.19723/j.issn.1671-167X.2022.05.013.

本文引用的文献

1
Estrogen and Progesterone Receptor Testing in Breast Cancer: ASCO/CAP Guideline Update.
J Clin Oncol. 2020 Apr 20;38(12):1346-1366. doi: 10.1200/JCO.19.02309. Epub 2020 Jan 13.
3
Histologic heterogeneity of triple negative breast cancer: A National Cancer Centre Database analysis.
Eur J Cancer. 2018 Jul;98:48-58. doi: 10.1016/j.ejca.2018.04.011. Epub 2018 Jun 2.
6
MYBL1 rearrangements and MYB amplification in breast adenoid cystic carcinomas lacking the MYB-NFIB fusion gene.
J Pathol. 2018 Feb;244(2):143-150. doi: 10.1002/path.5006. Epub 2017 Dec 28.
7
The Spectrum of Triple-Negative Breast Disease: High- and Low-Grade Lesions.
Am J Pathol. 2017 Oct;187(10):2139-2151. doi: 10.1016/j.ajpath.2017.03.016. Epub 2017 Jul 20.
8
Triple-negative breast cancer: the importance of molecular and histologic subtyping, and recognition of low-grade variants.
NPJ Breast Cancer. 2016 Nov 16;2:16036. doi: 10.1038/npjbcancer.2016.36. eCollection 2016.
9
Immunoprofile of metaplastic carcinomas of the breast.
Histopathology. 2017 May;70(6):975-985. doi: 10.1111/his.13159. Epub 2017 Mar 2.
10
Clinical implications of molecular heterogeneity in triple negative breast cancer.
Breast. 2015 Nov;24 Suppl 2(0 2):S36-40. doi: 10.1016/j.breast.2015.07.009. Epub 2015 Aug 5.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验